⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12154036 | 1.00 | — | — | |
| SCHEMBL11934549 | 1.00 | — | — | |
| SCHEMBL10045290 | 1.00 | — | — | |
| SCHEMBL10357880 | 1.00 | — | — | |
| SCHEMBL13084557 | 0.84 | — | — | |
| SCHEMBL11934544 | 0.83 | — | — | |
| SCHEMBL10045288 | 0.83 | — | — | |
| SCHEMBL11937053 | 0.83 | — | — | |
| SCHEMBL732693 | 0.83 | — | — | |
| SCHEMBL403118 | 0.82 | CYP2C9 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791069-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8574544-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8535640-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8501711-B2 | Acylated 1,6-anhydro decasaccharide and its use as an antithrombotic agent | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8461316-B1 | Nanoparticles for delivery of bioactive agents | GP MEDICAL, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8449915-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8383082-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8361439-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8354094-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8349799-B1 | Pharmaceutical composition of nanoparticles | GP MEDICAL, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090142405-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-7541046-B1 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090011008-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-01-08 | — | — | US | disclosed |
| US-20090004266-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-7455830-B2 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080233200-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080160078-A1 | Nanoparticles for drug delivery | GP MEDICAL, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7381716-B2 | Nanoparticles for protein drug delivery | GP MEDICAL, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| US-20070116771-A1 | Nanoparticles for protein drug delivery | NANOMEGA MEDICAL CORPORATION | 2007-05-24 | — | — | US | disclosed |